Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, USA, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, USA, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15Cytel Inc., Cambridge, MA, USA, 16University Hospitals Leuven, Leuven, Belgium

DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, B. Sands2, T. Kobayashi3, J. Tuttle4, J. Schmitz5, M. Durante5, R. Higgs5, J. B. Canavan5, R. Siegel5, M. Ferrante6

1University California San Diego, La Jolla, California, USA, 2Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Eli Lilly and Company, Lilly Biotechnology Center, San Diego, CA, USA, 5Eli Lilly and Company, Indianapolis, IN, USA, 6UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Sandborn1, D. Nguyen2, B. Ferslew2, L-Y. Hao3, T. Kanno3, L. Tomsho3, D. Boyle1, R. Graham2, B. Abhyankar2, J. Panes*4

1University of California San Diego, Medicine, San Diego, USA, 2Theravance Biopharma US, Inc., South San Francisco, USA, 3Janssen R&D, Springhouse, USA, 4Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain

DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese*1, B. E. Sands2, C. D. O'Brien3, H. Zhang3, J. Johanns3, S. Sloan3, J. Izanec4, P. Szapary3, C. Marano3, R. W. Leong5,6, D. Rowbotham7,8, S. R. Targan9, G. Van Assche10

1Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Janssen Scientific Affairs, LLC, Horsham, USA, 5Concord Hospital, Sydney, Australia, 6Macquarie University Hospital, Sydney, Australia, 7Auckland City Hospital, Auckland, New Zealand, 8University of Auckland, Auckland, New Zealand, 9Cedars-Sinai Medical Center, Los Angeles, USA, 10University of Leuven, Leuven, Belgium

DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing

ECCO '19 Copenhagen

Year: 2019
Authors:

E. S. Jung*1,2, K-w. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2

1Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, 2Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, 3National Institute of Food and Drug Safety Evaluation, Clinical Research Division, Cheongju, South Korea

DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Strik*1,2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D'Haens2

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Amsterdam UMC, location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Amsterdam UMC, Location AMC, Hospital Pharmacy, Amsterdam, The Netherlands, 4Projections Research Inc., Phoenixville, USA, 5Tergooi Hospital, Blaricum, The Netherlands, 6Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 7Amsterdam UMC, location AMC, Clinical Genetics, Amsterdam, The Netherlands, 8Amsterdam UMC, location VuMc, Gastroenterology and Hepatology, Amsterdam, The Netherlands

DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Maaser*1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1

1University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany, 2Gastroenterology Practice, Oldenburg, Germany, 3Biostatistik Tuebingen, Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co.KG, Medical Department Gastroenterology, Wiesbaden, Germany

DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

G. H. Huynh*1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4

1University of Alberta, Paediatrics, Edmonton, Canada, 2Hospital for Sick Children, University of Toronto, Paediatrics, Toronto, Canada, 3The Children's Hospital University of Manitoba, Paediatrics, Winnipeg, Canada, 4Stollery Children's Hospital University of Alberta, Paediatrics, Edmonton, Canada, 5Alberta Health Services, Biochemistry, Edmonton, Canada, 6Alberta Health Services, Paediatrics, Edmonton, Canada, 7Alberta Children's Hospital University of Calgary, Paediatrics and Community Health Sciences, Calgary, Canada, 8Projections Research, Phoenixville, USA

DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Raimundo Fernandes*1, S. Bernardo1, C. Simões1, L. Correia1, P. Moura Santos1, A. Rita Gonçalves1, A. Valente1, C. Baldaia1, R. Tato Marinho1

1Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastrenterology and Hepatology Unit, Lisbon, Portugal

DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Pavlidis*1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. Hayee3, G. Bewick1, N. Powell1

1King's College London, London, UK, 2BRC Bioinformatics core, London, UK, 3King's College Hospital, London, UK

DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Worley*1,2, A. Almoudaris1,2, P. Bassett3,4, J. Segal1,2, A. Akbar2,4, P. Aylin5, O. Faiz1,2

1St Mark's Hospital and Academic Institute, Surgical Epidemiology Trials and Outcome Centre, London, UK, 2Imperial College London, Department of Surgery and Cancer, London, UK, 3Statsconsultancy Ltd., Buckinghamshire, UK, 4St Mark's Hospital and Academic Institute, London, UK, 5Imperial College London, Dr Foster Unit, Department of Primary Care and Public Health, London, UK

DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, B. I. Jang2, V. Borzan3, A. Lahat4,5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12

1Medical University Vienna, Vienna, Austria, 2Yeungnam University Hospital, Daegu, South Korea, 3Clinical Hospital Center Osijek, Osijek, Croatia, 4Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 5Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Pauls Stradins Clinical University Hospital, Rīga, Latvia, 7Novosibirsk State Medical University, Novosibirsk, Russian Federation, 8Private Small_Scale Enterprise Medical Centre ‘Pulse’, Vinnytsya, Ukraine, 9University Hospital Schleswig-Holstein, Kiel, Germany, 10Sheba Medical Center, Tel Hashomer, Israel, 11Celltrion, Inc., Incheon, South Korea, 12Asan Medical Center, Seoul, South Korea

DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort studyECCO '19 Copenhagen
Year: 2019
Authors: G. Pineton de Chambrun1, B. Pariente2, P. Seksik3, R. Altwegg1, L. Vuitton4, C. Stefasnescu5, S. Nancey6, A. Aubourg7, M. Serrero8, L. Peyrin-Biroulet9, J. Filippi10, S. Viennot11, V. Abitbol12, M. Boualit13, A. Boureille14, J. Moreau15, A. Buisson16, X. Roblin17, M. Nachury2, M. Zappa18, J. Lambert19, Y. Bouhnik5, GETAID-MICA studygroup1

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Lille University Hospital, Gastroenterology, Lille, France, 3Saint-Antoine University Hospital, Gastroenterology, Paris, France, 4Besançon University Hospital, Gastroenterology, Besançon, France, 5Beaujon University Hospital, Gastroenterology, Clichy, France, 6Lyon University Hospital, Gastroenterology, Lyon, France, 7Tours University Hospital, Gastroenterology, Tours, France, 8Marseille University Hospital, Gastroenterology, Marseille, France, 9Nancy University Hospital, Gastroenterology, Vandoeuvre-les-Nancy, France, 10Nice University Hospital, Gastroenterology, Nice, France, 11Caen University Hospital, Gastroenterology, Caen, France, 12Cochin University Hospital, Gastroenterology, Paris, France, 13Valenciennes General Hospital, Gastroenterology, Valenciennes, France, 14Nantes University Hospital, Gastroenterology, Nantes, France, 15Toulouse University Hospital, Gastroenterology, Toulouse, France, 16Clermont-Ferrand University Hospital, Gastroenterology, Clermont-Ferrand, France, 17Saint-Etienne University Hospital, Gastroenterology, Saint-Etienne, France, 18Beaujon University Hospital, Radiology, Clichy, France, 19Saint-Louis University Hospital, Biostatistics, Paris, France

DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

L-Y. Mak*1, L. Chen2, T. Tong2, S. Lau2, W-K. Leung2

1Queen Mary Hospital, Medicine, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong

DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Noh*1, E. H. Oh1, S. H. Park2,3, J. B. Lee4, J. Y. Kim1, J. C. Park1, J. Kim1, N. Ham1, E. M. Song1, S. H. Park1,3, S. W. Hwang1,3, D. H. Yang1, J. S. Byeon1, S. J. Myung1, S. K. Yang1,3, B. D. Ye1,3

1Asan Medical Center, Gastroenterology, Seoul, South Korea, 2Asan Medical Center, Radiology, Seoul, South Korea, 3Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, South Korea, 4Asan Medical Center, Clinical Epidemiology and Biostatistics, Seoul, South Korea

DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Hu*1, G. Nguyen2, J. Rangrej3, J. Marshall1, N. Narula1

1McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, Canada, 2University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada, 3Ministry of Health and Long-Term Care, Health Analytics Branch, Toronto, Canada

DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Klenske*1, R. Atreya1, A. Hartmann2, S. Fischer1, S. Hirschmann1, S. Zundler1, M. Iacucci3, M. Neurath1, T. Rath1

1University Hospital of Erlangen, Department of Medicine 1, Division of Gastroenterology, Erlangen, Germany, 2University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany, 3University of Birmingham, Institute of Translational Medicine, Birmingham, UK

DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse-free survival in patients with ulcerative colitis in clinical and endoscopic remission

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Wang*1, I. Fewings2, L. Bornman1, B. Shadbolt3, M. Fadia2, K. Subramaniam1,4

1Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia, 2ACT Pathology, Canberra Hospital, Canberra, Australia, 3Health Analytics Research Centre, Canberra Hospital, Canberra, Australia, 4ANU Medical School, Australian National University, Canberra, Australia

DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with ulcerative colitis: a sub-analysis of the Navigator Study

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Watanabe*1,2, M. Esaki3, S. Oka4, F. Shimamoto5, M. Nishishita2, T. Fukuchi6, S. Fujii7, F. Hirai8, K. Kakimoto9, T. Inoue9, H. Kashida10, K. Takeuchi11, N. Ohmiya12, M. Saruta13, S. Saito14, Y. Saito15, S. Tanaka16, Y. Ajioka17, H. Tajiri13

1Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan, 2Nishishita GI Hospital, Osaka, Japan, 3Saga University, Saga, Japan, 4Hiroshima University, Hiroshima, Jamaica, 5Prefectural University of Hiroshima, Hiroshima, Japan, 6Osakafu Saiseikai Nakatsu Hospital, Osaka, Japan, 7Kyoto Katsura Hospital, Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Fukuoka, Japan, 9Osaka Medical College, Osaka, Japan, 10Kinki University, Osaka, Japan, 11Toho University Sakura Medical Center, Chiba, Japan, 12Fujita Medical University, Aichi, Japan, 13The Jikei University School of Medicine, Tokyo, Japan, 14The Cancer Institute Hospital of JFCR, Tokyo, Japan, 15National Cancer Center Hospital, Tokyo, Japan, 16Hiroshima University, Hiroshima, Japan, 17Niigata University, Niigata, Japan

DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, P. Sudahakar2,3,4, B. Creyns5, S. Verstockt6, J. Cremer5, W-J. Wollants2, S. Organe2, T. Korcsmaros3,4, M. Madgwick3, G. Van Assche1,2, C. Breynaert5, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Earlham Institute, Norwich, UK, 4Quadram Institute, Norwich, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium, 6KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium